Abstract
Introduction

51
Cryptococcus neoformans is an opportunistic pathogen and that infects individuals who have severe 52 immunodeficiencies such as late-stage HIV infection. C. neoformans is estimated to infect up to 1 million 53 individuals each year globally and causes hundreds of thousands of deaths (1,2). C. neoformans infection 54 begins as a respiratory infection but in the absence of an effective immune response the fungus 55 disseminates to the central nervous system causing meningitis, and eventually death (3,4). C. neoformans 56 initially grows within the alveolar spaces of the lungs as budding yeast before it is phagocytosed by 57 macrophages. In normal immunity, macrophages must become activated by further inflammatory signals 58 from the host immune system before they can effectively kill C. neoformans (5, 6) . When this does not occur 59 macrophages cannot kill C. neoformans; instead the fungus is able to proliferate rapidly intracellularly and 60 may use macrophages to disseminate to the central nervous system where it causes fatal meningitis (7-9).
62
An important group of inflammatory mediators produced during the initial stages of microbial infection by 63 macrophages are eicosanoids. Eicosanoids are a diverse group of potent lipid signalling molecules that 64 have a short range of action and communicate through autocrine or paracrine routes. During infection 65 macrophages produce large amounts of a particular group of eicosanoids called prostaglandins (10, 11) .
66
Prostaglandins have a number of physiological effects throughout the body, but in the context of immunity 67 they are known to strongly influence the inflammatory state(12). Two particular prostaglandins -PGE2 and 68 PGD2 -are the best-studied eicosanoid inflammatory mediators. During infection macrophages produce 69 both PGE2 and PGD2 and, via autocrine routes, macrophages are highly responsive to PGE2 and PGD2
70
(12). In vertebrate immunity, the synthesis of eicosanoids such as PGE2 is carefully regulated by feedback 71 loops to ensure that the potent effects of these molecules are properly constrained. Exogenous sources of 72 eicosanoids within the body, such as from eicosanoid-producing parasites (13) or tumours that overproduce 73 eicosanoids (14,15), disrupt host inflammatory signaling as they are not subject to the same regulation.
75
During infection, C. neoformans produces a range of eicosanoid species which are indistinguishable from 76 those produced by their vertebrate hosts (16) (17) (18) . Currently only two C. neoformans enzymes -77 phospholipase B1 and laccase -are known to be associated with cryptococcal eicosanoid synthesis (18, 19 
140
This suggests that there is a secreted factor produced by H99, but absent in Δplb1 that can promote 141 intracellular proliferation within macrophages.
143
PGE2 synthesis by C. neoformans is required for growth in vivo.
145
After showing that PGE2 produced by C. neoformans promotes in vitro fungal growth within macrophages 146 we wanted to see if these interactions could be reproduced in vivo. Zebrafish have been proven to be an 147 excellent model for understanding vertebrate eicosanoid biology (26,27) so we chose to investigate these 148 interactions using our zebrafish model of cryptococcosis (22). One of the advantages of this infection model 149 is that because we use fluorescently tagged C. neoformans strains, the fungal burden within infected larvae 150 can be non-invasively imaged throughout infection. To use Δplb1 with our zebrafish larvae infection model 151 we generated a constitutively expressed GFP tagged version of the Δplb1 (Δplb1-GFP). We next evaluated 152 the growth of Δplb1-GFP by infecting zebrafish larval with Δplb1-GFP and measuring the growth of the 153 fungus at 1,2 and 3 days post infection (dpi). Analysis of fungal burden revealed that Δplb1-GFP had a 154 lower fungal burden at 1, 2 and 3 days post infection compared to the parental strain H99-GFP (Fig 2A, C) .
155
These data show that the Δplb1 mutant has a similar growth deficiency in our in vivo model to our in vitro 156 data and previous studies (21, 23, 28 
168
PGE2 produced by C. neoformans can be further converted into 15-keto-PGE2 (18). Due to the possibility 169 that some of the PGE2 added to zebrafish might be converted to 15-keto-PGE2 we wanted to determine if 170 the effects we observed were due to the activity of PGE2 or 15-keto-PGE2. To test this, we treated infected 171 larvae with 16,16-dimethyl PGE2, which cannot be dehydrogenated into 15-keto-PGE2, but otherwise has 172 comparable activity to PGE2 (29). Interestingly, in contrast to PGE2, we found that 16,16-dimethyl PGE2 173 treatment did not increase the fungal burden of Δplb1-GFP (Fig 4E and 4G , p= 0.9782) or H99-GFP infected 174 larvae (Fig 4A and 4C , p= 0.9954). To confirm that C. neoformans growth rate is facilitated by 15-keto-
175
PGE2 we treated infected larvae with exogenous 15-keto-PGE2 and found that this was sufficient to 176 significantly increase the fungal burden of both Δplb1-GFP (Fig 4F and 4H , p = 0.0119, 1.56-fold increase 177 vs. DMSO) and H99-GFP infections (Fig 4B and 4C, activating host PPAR-we treated infected larvae with a specific agonist of PPAR--Troglitazone (TLT) -
191
at a concentration (0.55 µM) shown to strongly activate PPAR-in zebrafish larvae (31). We found that TLT 192 treatment produced a significantly increased the fungal burden of Δplb1-GFP (Fig 5B and 5D, 
197
In conclusion, we have shown for the first time that eicosanoids produced by C. neoformans are required
198
for virulence both in vitro and in vivo. We have shown that the intracellular growth defect of Δplb1 (21, 23) 199 can be rescued with the addition of exogenous PGE2 (Fig 1A) . Furthermore, with our co-infection 200 experiments we provide evidence that the source of this eicosanoid during infection is from the pathogen,
201
rather than the host (Fig 1 B) . Using a zebrafish larvae in vivo model of cryptococcosis we have gone on to 202 show that a recently described fungal burden defect during larval infection can also be rescued with the 203 addition of PGE2 (Fig 2) . Additionally we find that that PGE2 appears to require dehydrogenated into 15-204 keto PGE2 before it has a biological effect (Fig 2 and 3) . Finally, we provide evidence that the mechanism 
212
We have identified an unknown mechanism used by C. neoformans to manipulate host innate immunity 213 whereby eicosanoids secreted by the fungus are able to manipulate the function of macrophages and 214 promote fungal growth in the host through 15-keto PGE2 and the host receptor PPAR-.
215
We have previously identified that the PLB1 gene deletion mutant Δplb1 was deficient in replication and 216 survival in macrophages (21), an observation also supported by a number of studies using different in vitro 217 infection assays (19, 23) . In this study we have shown that the treating Δplb1 infected macrophages with 218 exogenous prostaglandin E2 is sufficient to restore intracellular proliferation of Δplb1. During cryptococcal 219 respiratory infection it has been observed that PGE2 levels increase significantly in the lung (20). Our study 220 identifies cryptococci as the source of PGE2 and additionally it identifies the direct effect of PGE2 on
221
Cryptococcus intracellular proliferation, confirming PGE2 as virulence factor required for growth in 222 macrophages. As a PGE2 is a phospholipase B1 dependent factor we hypothesised that co-infection would 223 also be sufficient to recover intracellular growth in macrophages. Analysis of complementary ratios of 224 mutant to parental strain numbers in co-infected macrophages demonstrated rescue, supporting our 225 conclusion that cryptococcal derived PGE2 is required for virulence.
226
A key goal of this study was to investigate how eicosanoids produced by C. neoformans may affect 227 pathogenesis within a living host. We chose to use a zebrafish larvae model of cryptococcosis that our 228 group has recently developed (22). To facilitate non-invasive fungal burden measurement within live larvae 229 we created a GFP-tagged Δplb1 strain with constitutive expression (Δplb1-GFP) to use alongside the GFP-230 tagged H99 parental strain we have previously produced (25). To our knowledge this is the first GFP tagged 231 version of Δplb1 created, and it also represents one of the only examples of a fluorescently tagged mutant 232 C. neoformans strain. Characterisation of Δplb1-GFP using our zebrafish model of cryptococcosis revealed 233 that this strain also has significantly reduced growth in vivo compared to H99-GFP, these findings confirm 234 findings from a similar zebrafish cryptococcosis model which also found that Δplb1 (non-fluorescent) had 235 attenuated burden during larval infection (32).
236
To ascertain whether PGE2 is also required for cryptococcal growth in vivo we treated zebrafish larvae 237 infected with Δplb1-GFP or H99-GFP with exogenous PGE2. In agreement with our in vitro findings we 238 10 found that PGE2 significantly improved the growth of Δplb1-GFP within larvae. Interestingly we also found 239 that PGE2 improved the growth of our H99-GFP parental control perhaps representing a wider manipulation 240 of host immunity in in vivo infection. During larval infection, C. neoformans interacts closely with 241 macrophages, it is therefore likely that the PGE2 dependent growth observed in our in vivo model is due to 242 host macrophage manipulation facilitated by Cryptococcus derived eicosanoids.
243
In vertebrate cells, PGE2 is converted into 15-keto PGE2 by the dehydrogenase enzyme 15-prostaglandin 244 dehydrogenase (15PGDH). To determine whether the biological effect we observed with PGE2 were 245 affected by the conversion of to PGE2 or 15-keto PGE2 we treated infected larvae with 16,16 dm-PGE2 -a 246 synthetic variant of PGE2 which is resistant to dehydrogenation (29). Interestingly we found that 16,16 dm-
247
PGE2 was not able to promote the growth of Δplb1-GFP or H99-GFP within infected larvae. These findings 248 indicated that 15-keto PGE2, rather than PGE2, was the bioactive molecule during cryptococcal infection.
249
To confirm these findings, we treated infected larvae with exogenous 15-keto-PGE2 and found that 15-keto-
250
PGE2 treatment was sufficient to promote the growth of both Δplb1-GFP and H99-GFP without the need for 251 PGE2. We propose that PGE2 produced by C. neoformans is enzymatically dehyodrogenated into 15-keto 252 PGE2, as previously mentioned the vertebrate enzyme 15PGDH can convert PGE2 into 15-keto PGE2,
253
additionally it has been reported that C. neoformans itself has enzymatic activity analogous to 15PGDH
254
(18), therefore it is possible that C. neoformans may produce both PGE2 and 15-keto-PGE2. These findings 255 represent the identification of a new virulence factor produced by C. neoformans as well as the first time 256 that an eicosanoid other than PGE2 has been identified as promoting cryptococcal growth. Furthermore, 257 our findings suggest that previous studies which identify PGE2 as a promoter of cryptococcal virulence 258 (19, 20, 33) may have observed multiplicative effects from both PGE2 and 15-keto PGE2 activity.
260
The biological activity of 15-keto PGE2 is far less studied than its parent species PGE2. 15-keto PGE2 is 261 unable to bind to the prostaglandin E2 EP receptors which means that one of its physiological functions is 262 to act as a negative regulator of PGE2 activity i.e. cells up-regulate 15PGDH activity to lower PGE2 levels troglitazone -a specific PPAR-agonist -at a concentration previously shown to activate PPAR-in 280 zebrafish larvae. At this concentration we found that troglitazone was able to increase the growth of Δplb1-
281
GFP and H99-GFP during infection. Although these findings strongly suggest that the cryptococcal growth 282 promoting effects of 15-keto PGE2 may mediated via activation of PPAR-, further work will be needed to 283 prove that the effects we observe when PPAR-is activated by troglitazone are due to the activity 15-keto 284 PGE2.
285
In conclusion we have shown for the first time that synthesis of eicosanoids by C. neoformans is able to 286 promote intracellular growth within macrophages and within an in vivo host. Additionally, we have 287 uncovered a new virulence factor -15-keto-PGE2 -that is produced from PGE2 during infection. We provide 288 evidence for a possible mechanism for 15-keto PGE2 via activation of PPAR-which is known to promote 
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Materials and methods 293
(all reagents are from Sigma-Aldrich, UK unless otherwise stated) 294
Ethics statement 295
Animal work was performed following UK law: Animal (Scientific Procedures) Act 1986, under 296
Project License PPL 40/3574. Ethical approval was granted by the University of Sheffield Local 297 Ethical Review Panel. 298
Zebrafish 299
All zebrafish used in this study were the Nacre wild type strain. Zebrafish were maintained 300 according to standard protocols. Adult fish were maintained on a 14:10 -hour light / dark cycle at 301 
C. neoformans 304
The H99-GFP has been previously described (25). The Δplb1-GFP was generated for this study 305 by transforming existing deletion mutant strains Δplb1 (23) C. neoformans strains Δplb1 was biolistically transformed using the pAG32_GFP transformation 316 construct as previously described for H99-GFP (25). Stable transformants were identified by 317 passaging positive GFP fluorescent colonies for at least 3 passages on YPD agar supplemented 318 with 250 µg/ml Hygromycin B. Two stable Δplb1-GFP transformants were identified (#1-1 and #1-319 2), this study uses #1-2 as it was determined to be have the strongest and most homogenous 320 GFP signal. 321
J774 Macrophage infection -with exogenous PGE2 treatment 322
J774 macrophage infection was performed as previously described (21) 
Zebrafish infection 364
Washed and counted Cryptococcus cells were pelleted at 3300g for 1 minute and re-suspended 365 in 10% Polyvinylpyrrolidinone (PVP), 0.5% Phenol Red in PBS to give the required inoculum in 1 366 nl. This injection fluid was loaded into glass capillaries shaped with a needle puller for 367 microinjection. Zebrafish larvae were injected at 2-days post fertilisation; the embryos were 368 anesthetised by immersion in 0.168 mg/ml tricaine in E3 before being transferred onto microscope 369 slides coated with 3% methyl cellulose in E3 for injection. Prepared larvae were injected with two 370 0.5 nl boluses of injection fluid by compressed air into the yolk sac circulation valley. Following 371 injection, larvae were removed from the glass slide and transferred to E3 to recover from 372 anaesthetic and then transferred to fresh E3 to remove residual methyl cellulose. Successfully 373 infected larvae (displaying systemic infection throughout the body and no visible signs of damage 374 resulting from injection) were sorted using a fluorescent stereomicroscope. Infected larvae were 375 maintained at 28 o C. 376
Eicosanoid / receptor agonist treatment of infected zebrafish larvae 377
All compounds below were purchased from Cayman Chemical. Compounds were resuspended 378 in DMSO and stored at -20 o C until used. Prostaglandin E2 (CAY14010, 10mg/ml stock), 379
Prostaglandin D2 (CAY12010, 10mg/ml stock), 16,16-dimethyl PGE2 (CAY14750, 10mg/ml 380 stock), 15-keto PGE2 (CAY14720, 10mg/ml stock) and troglitazone (CAY14720, 10mg/ml stock). 381
Treatment with exogenous compounds during larval infected was performed by adding 382 compounds (or equivalent solvent) to fish water (E3) to achieve the desired concentration. Fish 383 were immersed in compound supplemented E3 throughout the experiment from the time of 384 injection. 385
Zebrafish fungal burden measurement 386
Individual infected zebrafish embryos were placed into single wells of a 96 well plate (VWR) with 387 200 ul or E3 (unsupplemented E3, or E3 supplemented with eicosanoids / receptor agonist 388 depending on the assay). Infected embryos were imaged at 0 days post infection (dpi), 1 dpi, 2 389 dpi and 3 dpi in their 96 well plates using a Nikon Ti-E with a CFI Plan Achromat UW 2X N.A 0.06 390 objective lens. Images were captured with a Neo sCMOS (Andor, Belfast, UK) and NIS Elements 391 (Nikon, Richmond, UK). Images were exported from NIS Elements into Image J FIJI as 392 monochrome tif files. Images were threshholded in FIJI using the 'moments' threshold preset and 393 converted to binary images to remove all pixels in the image that did not correspond to the 394 intensity of the fluorescently tagged C. neoformans. The outline of the embryo was traced using 395 the 'polygon' ROI tool, avoiding autofluorescence from the yolk sac. The total number of pixels in 396 the threshholded image were counted using the FIJI 'analyse particles' function, the 'total area' 397 measurement from the 'summary' readout was used for the total number of GFP + pixels in each 398 embryo. 399
